Edwards Lifesciences
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.About EW
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.
EW Key Statistics
EW News
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Edwards Lifesciences (EW) been one of th...
Edwards Lifesciences (EW) has been beaten down lately with too much selling pressure. While the stock has lost 10.2% over the past four weeks, there is light at...
Loading... Loading... On CNBC's “Mad Money Lightning Round,” Jim Cramer said the new product line of Edwards Lifesciences Corporation EW is “pulling back here....
Analyst ratings
53%
of 32 ratingsMore EW News
Edwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call Transcript April 25, 2024 Edwards Lifesciences Corporation beats earnings expectations. Report...
Have you looked into how Edwards Lifesciences (EW) performed internationally during the quarter ending March 2024? Considering the widespread global presence of...
Let's talk about the popular Edwards Lifesciences Corporation ( ). The company's shares saw a decent share price growth of 19% on the NYSE over the last few mon...
Edwards Lifesciences (NYSE:EW) First Quarter 2024 Results Key Financial Results Revenue: US$1.60b (up 9.5% from 1Q 2023). Net income: US$351.9m (up 3.3% from...
Edwards Lifesciences Corporation EW reported adjusted earnings per share (EPS) of 66 cents in first-quarter 2024, surpassing the Zacks Consensus Estimate by 3.1...
Canaccord lowered the firm’s price target on Edwards Lifesciences to $85 from $86 and keeps a Buy rating on the shares. The firm said TAVR sales were slightly b...
Edwards Lifesciences (EW) reported $1.6 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $0.66 for th...